Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2025 | $95.00 → $68.00 | Neutral → Underperform | BofA Securities |
| 12/6/2024 | $116.00 | Overweight | Analyst |
| 11/8/2024 | $120.00 | Outperform → Strong Buy | Raymond James |
| 9/13/2024 | $116.00 | Buy | CL King |
| 9/11/2024 | $85.00 | Neutral | BofA Securities |
| 9/10/2024 | $112.00 | Buy | BTIG Research |
| 6/12/2024 | $112.00 | Hold → Buy | Needham |
| 10/13/2022 | $90.00 | Buy | Mizuho |
144 - HAEMONETICS CORP (0000313143) (Subject)
DEFA14A - HAEMONETICS CORP (0000313143) (Filer)
DEF 14A - HAEMONETICS CORP (0000313143) (Filer)
BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously
Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00